Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains killed virus particles that present the hemagglutinin and neuraminidase antigens of the selected influenza strains. When injected, these antigens stimulate the immune system to generate specific antibodies and cellular immunity, creating immunological memory that can neutralize the live virus if the person is later exposed.

The prescribed dose of Influvac is determined by the treating healthcare professional. Typically, a single vial is reconstituted with the supplied diluent and administered as a single intramuscular or subcutaneous injection. Annual revaccination is recommended to maintain protection against circulating strains.

Safety data for Influvac in pregnant or lactating women are limited. The vaccine may be used during pregnancy only if the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician, as the vaccine is not known to be harmful but data are insufficient for a definitive recommendation.

To place an order, submit an enquiry on the Influvac product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details (including cold‑chain logistics where applicable) and assists with any required import documentation.

Influvac is an inactivated, split‑virus vaccine that includes specific A and B strains recommended for the current flu season. Compared with live‑attenuated nasal sprays, it is administered by injection and is suitable for a broader population, including immunocompromised individuals. Its safety profile is similar to other inactivated vaccines, but strain composition may differ from alternative brands depending on regional regulatory approvals.

Influvac must be stored refrigerated at 2 °C to 8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. Once reconstituted, the suspension should be used immediately and discarded if not administered within the recommended time frame.

The vaccine is supplied as a lyophilized powder that is reconstituted with a sterile diluent immediately before use. The resulting suspension is injected intramuscularly, typically into the deltoid muscle, or subcutaneously according to the prescriber's instruction. Administration is performed by a qualified healthcare professional.

Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, high‑grade fever, seizures, and thrombocytopenia. Patients should be observed for at least 15 minutes after injection, and any signs of severe reaction—such as difficulty breathing, swelling of the face or throat, or neurological symptoms—require immediate medical attention.

Influvac should not be given to individuals with a known severe allergy to any component of the vaccine, including egg proteins, or to those who have experienced anaphylaxis after a previous influenza vaccine. It is also contraindicated for children younger than six months of age. Persons with a history of Guillain‑Barré syndrome should discuss risks with their physician before vaccination.